We're Making News

Immunity Pharma Announces Regulatory Approval for Phase 2a Follow-up Study in ALS

Jerusalem, Israel, February 6, 2018 – Immunity Pharma, a clinical-stage neurology-focused biopharmaceutical company, announced today that the Israel's Ministry of Health (MOH) has approved the clinical protocol for its extended Phase 2a Amyotrophic Lateral Sclerosis (ALS) study. The approval is for the continued treatment of ALS patients via intravenously administered IPL344 as a

...
Read More

Immunity Pharma Appoints Mr. Ron Pfeifer as Chairman of the Board

Jerusalem, Israel, October 1, 2017 - Immunity Pharma, a privately-held neurology-focused biopharmaceutical company, announced today that Mr. Ron Pfeifer was appointed as the chairman of its Board of Directors, after serving as a director since 2015. Mr. Pfeifer is an established investor with a track record of investing in dozens of breakthrough technology

...
Read More

Immunity Pharma Appoints Vice President of Research and Development

Jerusalem, Israel, July 27, 2017 - Immunity Pharma, a neurology-focused biopharmaceutical company, announced today that Dr. Ilana Cohen has joined Immunity Pharma as its Vice President of Research and Development. Dr. Cohen earned her PhD in neurobiology from the Weismann Institute of Science, Israel and did her postdoctoral training in the Department of Neurobiology at Stanford

...
Read More

Immunity Pharma Announces Passing a Two-Year Mark for Treating an ALS Patient with IPL344 under a Compassionate Treatment Protocol

Jerusalem, Israel, December 1, 2016 - Immunity Pharma, a neurology-focused biopharmaceutical company, announced today that it has passed a two-year mark for treating an ALS patient with IPL344 under a companionate treatment protocol. This ALS patient has been treated with intravenous injections of PL344 since December 1 2014. The patient entered the study 1.5 years after diagnosis

...
Read More